The global population genomics market was valued at USD 3.86 billion in 2025. The market is estimated at USD 4.31 billion in 2026 and is projected to reach USD 11.72 billion by 2036, at a CAGR of 10.5% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering national genomics programs, sequencing and genotyping technologies, data platforms and governance, funding models and public-private partnerships, cost per genome, the supplier landscape, and future growth opportunities.
The market covers sequencers and other instruments, consumables, services, and data software that national programs, biobanks, health systems, research consortia, and drug developers use to sequence, genotype, store, and analyze genomes at population scale. This includes short-read and long-read sequencers, genotyping arrays, library preparation and sequencing reagents, sequencing and genotyping services, analysis and interpretation services, bioinformatics software, and cloud-based trusted research environments. Programs increasingly link genetic data with health records, lifestyle data, and proteomic and epigenomic measurements. Individual clinical testing outside population programs, direct-to-consumer genetic testing, and non-human studies such as agricultural and microbial genomics are excluded.
All of Us, the flagship cohort funded by the National Institutes of Health (NIH) in the United States, counted more than 747,000 participants in June 2026, including whole genomes for 535,000 people, close to 482,000 connected health records, and over 1.3 billion variants, and more than 86% of its participants belong to groups that health research has long left out. In the UAE, the Emirati Genome Programme passed 600,000 sequenced genomes by late 2024, including 100,000 long-read genomes with epigenetic data, and is working toward one million samples. Funding remains a risk: NIH support for All of Us dropped to roughly USD 158 million in FY2025, about 71% less than in FY2023.
Reliance on public budgets is a key restraint, as cuts can delay recruitment, sequencing, and data release, as seen in the reduced NIH funding for All of Us. Genetic data are highly sensitive, and programs must comply with the EU General Data Protection Regulation and national laws such as the UAE's federal decree-law on the human genome, while the bankruptcy and sale of 23andMe heightened public concern over who owns and controls genetic data. Programs also face heavy data storage, computing, and bioinformatics demands, especially in emerging economies, and must show that sequencing improves outcomes and offers value for money to keep funding in place.
Newborn and preventive genomic screening is a significant opportunity; Genomics England's Generation Study aims to sequence 100,000 newborns and test whether genome sequencing can find more than 200 rare conditions, and the UAE has announced plans for premarital and newborn genome testing. Long-read and multiomic studies offer another opening, with UK Biobank profiling over 5,400 proteins across as many as 600,000 samples and Singapore's PRECISE-SG100K generating proteomic data. Demand is also rising for secure data platforms, as UK Biobank, All of Us, Our Future Health, and other cohorts provide access through cloud environments, and for programs in underrepresented groups across India, Southeast Asia, the Middle East, Africa, and Latin America. Key trends include the shift from arrays to sequencing, funding partnerships between health systems and drug developers, and the addition of proteomic and epigenetic data to population cohorts.
By offering, the population genomics market is segmented into consumables & reagents, instruments, services (sequencing & genotyping services and data analysis & interpretation services), and software & data platforms. Consumables & reagents are expected to account for the largest share in 2026, as sequencing reagents, library preparation kits, and arrays are used for every participant, and very large programs, from All of Us and the Truveta Genome Project to Our Future Health and the Emirati Genome Programme, consume them in high volume. Software & data platforms are expected to grow at the highest CAGR, driven by the rising size and complexity of datasets, the move to secure cloud-based research environments, and wider use of AI in analysis. Services hold a significant share through large contracts, such as Eurofins Genomics' selection to genotype up to 5 million Our Future Health participants.
By technology, the population genomics market is segmented into short-read whole-genome sequencing (WGS), whole-exome sequencing (WES), genotyping arrays, long-read sequencing, and multiomic technologies. Short-read WGS is expected to account for the largest share in 2026, as it is the standard method in leading programs such as All of Us and UK Biobank, high-throughput platforms keep lowering cost, and it captures far more information than arrays. Long-read sequencing is expected to grow at the highest CAGR, as it detects structural variants, repeat expansions, and methylation that other methods miss, it is used at scale in the Emirati Genome Programme, and long-read genome prices are falling. Whole-exome sequencing should grow strongly on the back of the Truveta Genome Project, while arrays remain important for the very largest cohorts.
By application, the population genomics market is segmented into disease research & drug discovery, precision medicine & clinical care, rare disease diagnosis, newborn & reproductive genomic screening, pharmacogenomics, and population health & ancestry research. Disease research & drug discovery is expected to account for the largest share in 2026, as population datasets are used mainly for research, drug developers fund sequencing and biobank partnerships, and genetic evidence improves the odds of clinical success. Newborn & reproductive genomic screening is expected to grow at the highest CAGR, supported by the Generation Study, the NHS 10 Year Health Plan's aim of sequencing for newborns, and the UAE's plans for premarital and newborn genome tests. Precision medicine and pharmacogenomics gain weight as genetic results enter routine care.
By end user, the population genomics market is segmented into government & national genomics programs, biobanks & research consortia, healthcare systems & hospitals, pharmaceutical & biotechnology companies, and academic & research institutes. Government & national genomics programs are expected to account for the largest share in 2026, as national efforts in the U.S., the U.K., India, the UAE, Saudi Arabia, and elsewhere pay for much of the sequencing performed today. Healthcare systems & hospitals are expected to grow at the highest CAGR, driven by health system projects such as the Truveta Genome Project, the use of genomics in diagnosis and prevention, and the value of linking exome data with clinical records. Pharmaceutical & biotechnology companies are also set for strong growth as they invest in population datasets.
North America is set to hold the largest share of the population genomics market in 2026, owing to large national and health system programs, a cluster of sequencing technology firms and service centers, and heavy drug industry spending on genetic data. In the U.S., All of Us, the Truveta Genome Project, and the Million Veteran Program, which has enrolled more than one million veterans, anchor demand, although lower NIH funding may slow publicly funded growth, while Canada contributes through provincial genomics initiatives. Europe holds a significant share, led by the U.K., where UK Biobank has made whole genomes for some 500,000 participants available and Our Future Health has enrolled more than 2 million consented volunteers. Finland, through FinnGen, Estonia, Denmark, France, and Germany are also important, and the European 1+ Million Genomes initiative is building the means to share genomic data between countries.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to large and genetically diverse populations, new national programs, and growing investment in precision medicine. China is expected to hold the largest share in the region, helped by large research cohorts and domestic sequencing suppliers, while India's GenomeIndia project and Singapore's PRECISE-SG100K add new demand, and Japan, South Korea, Taiwan, and Australia are set for strong growth through national biobanks. The Middle East & Africa is expected to grow strongly, led by the Emirati Genome Programme and national genome programs in Saudi Arabia and Qatar, while Latin America, led by Brazil and Mexico, holds a smaller share supported by studies of admixed populations.
The population genomics market is moderately consolidated, as a few sequencing and genotyping technology suppliers hold a significant share while large service laboratories, drug company genetics centers, data platform firms, and national genomics bodies compete for program contracts. Competition centers on cost per genome, throughput, data quality, the ability to capture structural variants and methylation, data security, platform capabilities, and capacity to deliver national-scale projects. Recent moves include the January 2025 start of the Truveta Genome Project, with sequencing by the Regeneron Genetics Center, UK Biobank's choice of Thermo Fisher Scientific and Ultima Genomics for its proteome study, Illumina's 5-Base Solution, launched in October 2025, PacBio's 2026 rollout of SPRQ-Nx chemistry, and the 2025 sale of 23andMe's assets to TTAM Research Institute after a rival Regeneron bid.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), Ultima Genomics, Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (Regeneron Genetics Center) (U.S.), Eurofins Scientific SE (Eurofins Genomics) (Luxembourg), M42 (UAE), and DNAnexus, Inc. (U.S.).
The market covers sequencers and other instruments, consumables, services, and data software that national programs, biobanks, health systems, research consortia, and drug developers use to sequence, genotype, store, and analyze genomes at population scale. This includes short-read and long-read sequencers, genotyping arrays, library preparation and sequencing reagents, sequencing and genotyping services, analysis and interpretation services, bioinformatics software, and cloud-based trusted research environments. Programs increasingly link genetic data with health records, lifestyle data, and proteomic and epigenomic measurements. Individual clinical testing outside population programs, direct-to-consumer genetic testing, and non-human studies such as agricultural and microbial genomics are excluded.
All of Us, the flagship cohort funded by the National Institutes of Health (NIH) in the United States, counted more than 747,000 participants in June 2026, including whole genomes for 535,000 people, close to 482,000 connected health records, and over 1.3 billion variants, and more than 86% of its participants belong to groups that health research has long left out. In the UAE, the Emirati Genome Programme passed 600,000 sequenced genomes by late 2024, including 100,000 long-read genomes with epigenetic data, and is working toward one million samples. Funding remains a risk: NIH support for All of Us dropped to roughly USD 158 million in FY2025, about 71% less than in FY2023.
Market Dynamics
National genomics programs are a major driver of the population genomics market, as governments fund large sequencing and genotyping efforts for precision medicine, public health, and research, and each program needs instruments, reagents, services, and data infrastructure. India released 10,000 whole genomes through the GenomeIndia project in January 2025, and its Ministry of Science and Technology aims to sequence about 10 million genomes. Health systems are linking genetic data to clinical records; the Truveta Genome Project, started in January 2025 by Truveta with over 30 U.S. health systems, plans to sequence exomes from its first 10 million volunteers through the Regeneron Genetics Center. Drug developers value targets backed by human genetic evidence, and 14 biopharmaceutical companies fund the UK Biobank Pharma Proteomics Project. Lower sequencing costs, including PacBio's list price of USD 345 per long-read genome with SPRQ-Nx chemistry, are moving programs from arrays to whole-genome sequencing.Reliance on public budgets is a key restraint, as cuts can delay recruitment, sequencing, and data release, as seen in the reduced NIH funding for All of Us. Genetic data are highly sensitive, and programs must comply with the EU General Data Protection Regulation and national laws such as the UAE's federal decree-law on the human genome, while the bankruptcy and sale of 23andMe heightened public concern over who owns and controls genetic data. Programs also face heavy data storage, computing, and bioinformatics demands, especially in emerging economies, and must show that sequencing improves outcomes and offers value for money to keep funding in place.
Newborn and preventive genomic screening is a significant opportunity; Genomics England's Generation Study aims to sequence 100,000 newborns and test whether genome sequencing can find more than 200 rare conditions, and the UAE has announced plans for premarital and newborn genome testing. Long-read and multiomic studies offer another opening, with UK Biobank profiling over 5,400 proteins across as many as 600,000 samples and Singapore's PRECISE-SG100K generating proteomic data. Demand is also rising for secure data platforms, as UK Biobank, All of Us, Our Future Health, and other cohorts provide access through cloud environments, and for programs in underrepresented groups across India, Southeast Asia, the Middle East, Africa, and Latin America. Key trends include the shift from arrays to sequencing, funding partnerships between health systems and drug developers, and the addition of proteomic and epigenetic data to population cohorts.
Segment Analysis
The report analyzes the market by offering, technology, application, end user, and geography, helping stakeholders identify the most attractive areas for investment, partnering, and program design.By offering, the population genomics market is segmented into consumables & reagents, instruments, services (sequencing & genotyping services and data analysis & interpretation services), and software & data platforms. Consumables & reagents are expected to account for the largest share in 2026, as sequencing reagents, library preparation kits, and arrays are used for every participant, and very large programs, from All of Us and the Truveta Genome Project to Our Future Health and the Emirati Genome Programme, consume them in high volume. Software & data platforms are expected to grow at the highest CAGR, driven by the rising size and complexity of datasets, the move to secure cloud-based research environments, and wider use of AI in analysis. Services hold a significant share through large contracts, such as Eurofins Genomics' selection to genotype up to 5 million Our Future Health participants.
By technology, the population genomics market is segmented into short-read whole-genome sequencing (WGS), whole-exome sequencing (WES), genotyping arrays, long-read sequencing, and multiomic technologies. Short-read WGS is expected to account for the largest share in 2026, as it is the standard method in leading programs such as All of Us and UK Biobank, high-throughput platforms keep lowering cost, and it captures far more information than arrays. Long-read sequencing is expected to grow at the highest CAGR, as it detects structural variants, repeat expansions, and methylation that other methods miss, it is used at scale in the Emirati Genome Programme, and long-read genome prices are falling. Whole-exome sequencing should grow strongly on the back of the Truveta Genome Project, while arrays remain important for the very largest cohorts.
By application, the population genomics market is segmented into disease research & drug discovery, precision medicine & clinical care, rare disease diagnosis, newborn & reproductive genomic screening, pharmacogenomics, and population health & ancestry research. Disease research & drug discovery is expected to account for the largest share in 2026, as population datasets are used mainly for research, drug developers fund sequencing and biobank partnerships, and genetic evidence improves the odds of clinical success. Newborn & reproductive genomic screening is expected to grow at the highest CAGR, supported by the Generation Study, the NHS 10 Year Health Plan's aim of sequencing for newborns, and the UAE's plans for premarital and newborn genome tests. Precision medicine and pharmacogenomics gain weight as genetic results enter routine care.
By end user, the population genomics market is segmented into government & national genomics programs, biobanks & research consortia, healthcare systems & hospitals, pharmaceutical & biotechnology companies, and academic & research institutes. Government & national genomics programs are expected to account for the largest share in 2026, as national efforts in the U.S., the U.K., India, the UAE, Saudi Arabia, and elsewhere pay for much of the sequencing performed today. Healthcare systems & hospitals are expected to grow at the highest CAGR, driven by health system projects such as the Truveta Genome Project, the use of genomics in diagnosis and prevention, and the value of linking exome data with clinical records. Pharmaceutical & biotechnology companies are also set for strong growth as they invest in population datasets.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, the Middle East & Africa, and Latin America, spanning 20 countries and four rest-of-region groups. The regional analysis of the population genomics market considers national program scale and funding, health system adoption, pharmaceutical investment, data governance rules, and local sequencing capacity.North America is set to hold the largest share of the population genomics market in 2026, owing to large national and health system programs, a cluster of sequencing technology firms and service centers, and heavy drug industry spending on genetic data. In the U.S., All of Us, the Truveta Genome Project, and the Million Veteran Program, which has enrolled more than one million veterans, anchor demand, although lower NIH funding may slow publicly funded growth, while Canada contributes through provincial genomics initiatives. Europe holds a significant share, led by the U.K., where UK Biobank has made whole genomes for some 500,000 participants available and Our Future Health has enrolled more than 2 million consented volunteers. Finland, through FinnGen, Estonia, Denmark, France, and Germany are also important, and the European 1+ Million Genomes initiative is building the means to share genomic data between countries.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to large and genetically diverse populations, new national programs, and growing investment in precision medicine. China is expected to hold the largest share in the region, helped by large research cohorts and domestic sequencing suppliers, while India's GenomeIndia project and Singapore's PRECISE-SG100K add new demand, and Japan, South Korea, Taiwan, and Australia are set for strong growth through national biobanks. The Middle East & Africa is expected to grow strongly, led by the Emirati Genome Programme and national genome programs in Saudi Arabia and Qatar, while Latin America, led by Brazil and Mexico, holds a smaller share supported by studies of admixed populations.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with company profiles covering business and financial overviews, population genomics portfolios, strategic developments, and SWOT analyses.The population genomics market is moderately consolidated, as a few sequencing and genotyping technology suppliers hold a significant share while large service laboratories, drug company genetics centers, data platform firms, and national genomics bodies compete for program contracts. Competition centers on cost per genome, throughput, data quality, the ability to capture structural variants and methylation, data security, platform capabilities, and capacity to deliver national-scale projects. Recent moves include the January 2025 start of the Truveta Genome Project, with sequencing by the Regeneron Genetics Center, UK Biobank's choice of Thermo Fisher Scientific and Ultima Genomics for its proteome study, Illumina's 5-Base Solution, launched in October 2025, PacBio's 2026 rollout of SPRQ-Nx chemistry, and the 2025 sale of 23andMe's assets to TTAM Research Institute after a rival Regeneron bid.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), Ultima Genomics, Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (Regeneron Genetics Center) (U.S.), Eurofins Scientific SE (Eurofins Genomics) (Luxembourg), M42 (UAE), and DNAnexus, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global population genomics market.
- Explains how national programs, health system sequencing, drug target discovery, and lower sequencing costs are driving demand.
- Assesses the impact of public funding limits, data privacy and consent rules, and data management needs on the market.
- Identifies high-growth opportunities across offering, technology, application, end user, and region.
- Tracks newborn genomic screening, long-read and multiomic population studies, and trusted research environments.
- Benchmarks leading companies by cost per genome, throughput, program contracts, and partnerships.
- Supports product planning, program bidding, partnering, and market entry decisions for suppliers and investors.
Key Questions Answered
- How big is the global population genomics market today, and how will it grow through 2036?
- Which national genomics programs are generating the most demand for sequencing and data platforms?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are funding models shifting among governments, health systems, and drug developers?
- Which offering, technology, application, and end user segments will grow the fastest?
- How quickly will long-read and multiomic data be added to population programs?
- Could newborn genomic screening become a routine and recurring source of demand?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they using?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Population Genomics Market, by Offering
6. Population Genomics Market, by Technology
7. Population Genomics Market, by Application
8. Population Genomics Market, by End User
9. Population Genomics Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- MGI Tech Co., Ltd.
- Ultima Genomics, Inc.
- Regeneron Pharmaceuticals, Inc.
- Eurofins Scientific SE
- M42
- DNAnexus, Inc.
